Table 3 Significant prognostic factors for survivals in newly-diagnosed patients with acute promyelocytic leukaemia treated with ATRA-based and oral-ATO-based regimens

ATRA-based regimens

Overall survival (N = 469)

Sex

 Male

239

1.39

1.08–1.79

0.01

1.41

1.08–1.82

0.012

 Female

230

0.72

0.56–0.93

0.71

0.55–0.93

Age

 ≤ 50 years

315

0.38

0.29–0.49

< 0.001

0.36

0.27–0.46

< 0.001

 > 50 years

154

2.62

2.03–3.39

2.81

2.16–3.66

Leucocyte count

 ≤ 10 × 10⁹/L

278

0.50

0.39–0.65

< 0.001

0.42

0.31–0.57

< 0.001

 > 10 × 10⁹/L

176

2.00

1.54–2.59

1.53

1.07–2.18

Sanz score

 Low-risk

83

0.65

0.46–0.92

< 0.001

0.65

0.46–9.30

< 0.001

 Intermediate-risk

196

0.44

0.33–0.59

0.41

0.31–0.56

 High-risk

176

1.55

1.09–2.20

1.53

1.08–2.18

Post-30-day survival (N = 331)

Age

 ≤ 50 years

247

0.31

0.21–0.45

< 0.001

0.26

0.17–0.39

< 0.001

 > 50 years

84

3.26

2.20–4.83

3.90

2.59–5.89

Sanz score

 Low-risk

83

1.06

0.64–1.17

0.02

0.92

0.55–1.54

0.001

 Intermediate-risk

196

0.57

0.36–0.91

0.45

0.28–0.72

 High-risk

176

0.94

0.57–1.57

1.09

0.65–1.82

Oral-ATO-based regimens

Overall survival (N = 282)

Age

 ≤ 50 years

156

0.44

0.21–0.92

0.03

-*

-

-

 > 50 years

256

3.26

1.09–4.66

-

-